Skip to content
Politically.com Search all
Menu

2026 · 2nd Quarter (Apr 1 - June 30)

BIOTECHNOLOGY INNOVATION ORGANIZATION

Filed by AKIN GUMP STRAUSS HAUER & FELD.

Open official filing
Source: Lobbying Disclosure APIRecently refreshed. 2026-09-14 06:26:07 UTC.

Source-reported fields

Filing overview

Type
2nd Quarter - Report
Posted
Jul 20, 2026
Income
$60,000.00
Expenses
Not reported
Filing UUID
68974659-b5c4-49fd-9cf7-0d1ae2d9c791
Termination date
Not reported

Literal source text

Lobbying issues and bill citations

SMB · Small Business

Issues related to the Small Business Innovation Research Program in the Small Business Innovation and Economic Security Act (P.L. 119-83).

HCR · Health Issues

Issues related to Rare Pediatric Disease Priority Review Voucher Program reauthorization; Issues related to H.R. 1262 / S. 3302 - Mikaela Naylon Give Kids a Chance Act of 2025; Issues related to the Consolidated Appropriations Act, 2026 (P.L. 119-75), including the extension of authority to issue priority review vouchers to encourage treatments for rare pediatric diseases; Issues related to the biotech ecosystem, including most-favored-nation drug pricing; Issues related to PBM reform, PAHPA reauthorization; and PDUFA reauthorization.

Literal federal measure citations: H.R. 1262, S. 3302

Relationship and amount limits

Bill links use only the filing year’s mathematically derived Congress plus the literal measure type and number in the issue description. Unmatched citations remain plain text. Politically.com does not join on names, infer advocacy positions, combine amendments, or calculate totals across filings.